Impaired NK cell cytotoxicity in multiple myeloma caused by the homozygous A91V polymorphism in the perforin gene: a case report
Citotoxicidade de células NK prejudicada no mieloma múltiplo causada pelo polimorfismo A91V em homozigose no gene da perforina: um relato de caso
DOI:
https://doi.org/10.34117/bjdv8n12-026Keywords:
perforin, granzyme b, multiple myeloma, natural killer cell, case reportAbstract
We describe a 58-year-old man diagnosed with IgG/Kappa multiple myeloma (International Staging System III) treated for eight years with polychemotherapy (VAD schee) and autologous peripheral hematopoietic stem cell transplantation. The patient studied was homozygous C272T polymorphism (PRF1272T/T) by analysis of perforin gene by direct sequencing. This SNP is considered pathogenic and leads to the substitution of the amino acid alanine for valine in codon 91 of the perforin protein. The cytotoxic lymphocytes (CLs) of the patient and of the healthy wild homozygous individual were evaluated for their cytotoxic capacity. Our results show that PRF1272T/T effector cells had significantly reduced ability to induce specific lysis of K562 cells. The NK cells of the patient had three times less intracellular perforin than observed in the wild-type individual. The gene expression of PRF1 and FAS did not differ between the individuals, however the expression of GZMB was approximately 2.5 times higher in the patient. It was also observed that the T-BET expression was approximately 1.7-fold higher and IFN-γ expression was 4.5-fold higher in the PRF1272T/T patient. In conclusion, functional analysis of the CLs of the patient revealed a significant decrease in their cytolytic capacity as well as the amount of perforin present in NK cell granules.
References
Fink TM, Zimmer M, Weitz S, Tschopp J, Jenne DE, et el. Human perforin (PRF1) maps to 10q22, a region that is syntenic with mouse chromosome 10. Genomics. 1992 Aug;13(4):1300-2. doi: 10.1016/0888-7543(92)90050-3.
Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015 Jun;15(6):388-400. doi: 10.1038/nri3839.
van den Broek ME, Kägi D, Ossendorp F, Toes R, Vamvakas S, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996 Nov 1;184(5):1781-90. doi: 10.1084/jem.184.5.1781.
Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000 Sep 4;192(5):755-60. doi: 10.1084/jem.192.5.755.
Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999 Dec 3;286(5446):1957-9. doi: 10.1126/science.286.5446.1957.
Göransdotter Ericson K, Fadeel B, Nilsson-Ardnor S, Söderhäll C, Samuelsson A, et al. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. Am J Hum Genet. 2001 Mar;68(3):590-7. doi: 10.1086/318796.
Santoro A, Cannella S, Trizzino A, Lo Nigro L, Corsello G, et al. A single amino acid change A91V in perforin: a novel, frequent predisposing factor to childhood acute lymphoblastic leukemia? Haematologica. 2005 May;90(5):697-8.
Clementi R, Locatelli F, Dupré L, Garaventa A, Emmi L, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood. 2005 Jun 1;105(11):4424-8. doi: 10.1182/blood-2004-04-1477.
Cannella S, Santoro A, Bruno G, Pillon M, Mussolin L, et al. Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma. Cancer. 2007 Jun 15;109(12):2566-71. doi: 10.1002/cncr.22718.
Brennan AJ, Chia J, Trapani JA, Voskoboinik I. Perforin deficiency and susceptibility to cancer. Cell Death Differ. 2010 Apr;17(4):607-15. doi: 10.1038/cdd.2009.212.
Trambas C, Gallo F, Pende D, Marcenaro S, Moretta L, et al. A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin. Blood. 2005 Aug 1;106(3):932-7. doi: 10.1182/blood-2004-09-3713.
Voskoboinik I, Thia MC, Trapani JA. A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis. Blood. 2005 Jun 15;105(12):4700-6. doi: 10.1182/blood-2004-12-4935.
Voskoboinik I, Trapani JA. Addressing the mysteries of perforin function. Immunol Cell Biol. 2006 Feb;84(1):66-71. doi: 10.1111/j.1440-1711.2005.01409.x.
Hungria VT, Maiolino A, Martinez G, Duarte GO, Bittencourt R, et al; International Myeloma Working Group Latin America. Observational study of multiple myeloma in Latin America. Ann Hematol. 2017 Jan;96(1):65-72. doi: 10.1007/s00277-016-2866-9.
Solomou EE, Gibellini F, Stewart B, Malide D, Berg M, et al. Perforin gene mutations in patients with acquired aplastic anemia. Blood. 2007 Jun 15;109(12):5234-7. doi: 10.1182/blood-2006-12-063495.
House IG, Thia K, Brennan AJ, Tothill R, Dobrovic A, et al. Heterozygosity for the common perforin mutation, p.A91V, impairs the cytotoxicity of primary natural killer cells from healthy individuals. Immunol Cell Biol. 2015 Jul;93(6):575-80. doi: 10.1038/icb.2015.1.
Jenkins MR, Rudd-Schmidt JA, Lopez JA, Ramsbottom KM, Mannering SI, et al. Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015 Mar 9;212(3):307-17. doi: 10.1084/jem.20140964.
Afkarian M, Sedy JR, Yang J, Jacobson NG, Cereb N, et al. T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells. Nat Immunol. 2002 Jun;3(6):549-57. doi: 10.1038/ni794.
Yu CR, Ortaldo JR, Curiel RE, Young HA, Anderson SK, et al. Role of a STAT binding site in the regulation of the human perforin promoter. J Immunol. 1999 Mar 1;162(5):2785-90.
Lehmann C, Zeis M, Uharek L. Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. Br J Haematol. 2001 Sep;114(3):660-5. doi: 10.1046/j.1365-2141.2001.02995.x.
Bae DS, Lee JK. Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line. Blood Res. 2014 Sep;49(3):154-61. doi: 10.5045/br.2014.49.3.154. Epub 2014 Sep 25.
Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998 Jun 1;187(11):1885-92. doi: 10.1084/jem.187.11.1885.
Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP, Fernandez-Guizan A, Payer AR, et al. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int. 2014;2014:265840. doi: 10.1155/2014/265840.
Lindner S, Krönke J. The molecular mechanism of thalidomide analogs in hematologic malignancies. J Mol Med (Berl). 2016 Dec;94(12):1327-1334. doi: 10.1007/s00109-016-1450-z.
